A Pilot Study of Trametinib plus Paclitaxel to Treat Anaplastic Thyroid Cancer

Full Title

A Pilot Study of Trametinib in Combination with Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

Purpose

Paclitaxel is a standard chemotherapy drug used to treat anaplastic thyroid cancer. Laboratory studies suggest it may be more effective when given with the drug trametinib. In this study, researchers are evaluating the combination of paclitaxel and trametinib in patients with metastatic or inoperable anaplastic thyroid cancer.

Trametinib works by blocking a protein involved in cancer growth called MEK. It is common for anaplastic thyroid cancer to have abnormalities in the MEK pathway. Trametinib is used to treat advanced melanoma; its use in this study is considered investigational. It is taken orally (by mouth). Paclitaxel is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic or inoperable anaplastic thyroid cancer.
  • At least 3 weeks must pass between the completion of any prior chemotherapy or radiation therapy and entry into the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Eric Sherman at 646-888-4234.

Protocol

15-055

Phase

Pilot

Investigator

Co-Investigators

Diseases